Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • nephrotoxicity
Cefazolin Is Non‑Inferior to Cloxacillin for MSSA Bacteraemia and Causes Less Kidney Injury: The CloCeBa Randomised Trial
Posted inInfectious Diseases news

Cefazolin Is Non‑Inferior to Cloxacillin for MSSA Bacteraemia and Causes Less Kidney Injury: The CloCeBa Randomised Trial

Posted by MedXY By MedXY 11/11/2025
The CloCeBa trial found cefazolin non‑inferior to cloxacillin for meticillin‑susceptible Staphylococcus aureus (MSSA) bacteraemia, with similar 90‑day composite outcomes and substantially lower rates of serious adverse events and acute kidney injury.
Read More
A‑E‑I‑O‑U and Sometimes Why—Dialysis in Acute Kidney Injury
Posted inNephrology news

A‑E‑I‑O‑U and Sometimes Why—Dialysis in Acute Kidney Injury

Posted by MedXY By MedXY 11/08/2025
LIBERATE‑D randomized hemodynamically stable patients with AKI to conservative vs conventional thrice‑weekly continuation of KRT; conservative discontinuation increased dialysis‑free recovery, shortened time to recovery, and reduced sessions without detectable harm, challenging automatic thrice‑weekly schedules.
Read More
  • Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns
  • Prenatal Maternal Depression as a Critical Developmental Risk Factor: Large-Scale IPD Meta-Analysis of 76,514 Children
  • The Tart Cherry Revolution: A Deep Dive into the Science of Longevity, Recovery, and Restorative Sleep
  • Restoring Movement: How Polylaminin is Revolutionizing Spinal Cord Injury Treatment
  • Antifibrotic Repurposing: How Finerenone Could Rejuvenate the Ovarian Niche and Restore Fertility in POI
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in